In this study, we investigated in a large well-described low- to intermediate-risk chest-pain cohort whether variation in plasma levels of soluble sortilin was under genetic influence and explored the added value of including soluble sortilin in risk stratification of patients with suspected CAD. The gene discussed is SORT1; the disease is coronary artery disorder.